The hERG screening market’s growth is slated to happen due to rise in the incidence of cardiac ailments followed by increase in frequency of innovation-based medical approvals. hERG assays are used for screening the compounds that are likely to block hERG potassium channel and delay heart’s QT interval that could cause fatal arrhythmias otherwise.
The companies operating in the hERG screening market are making efforts reach the unexplored geographies to widen the consumer base, thereby trying to contribute toward the reduction of fatalities caused by heart ailments. They are collaborating with the government and non-government agencies to create awareness campaigns regarding the same.
A hERG (Human Ether-a-go-go Related Gene) assay is amongst the laboratory techniques gauging hERG channel protein’s activity. The hERG activity manifests as movement of the potassium ions through pore that is seen in hERG channel protein.
hERG assays are amongst the essential components of nonclinical safety evaluation, which assess basis of drug-induced arrhythmia. The in vitro hERG patch clamp assays have turned out to be standard components with regards to cardiac safety evaluation during non-clinical drug development.
hERG assay can be used for supporting preclinical studies pertaining to heart ailments. They are also recommended in various discovery studies for supporting the cardiac programs.
hERG channel assay facilitates higher throughput as well as specificity with three diverse kinds of radioligands, thereby providing more reliable feedbacks.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Sedentary habits leading to by common risk factors such as hypertension, diabetes, and hypercholesterolemia are responsible for higher incidences of cardiovascular diseases. As an outcome, the market pertaining to drug discovery would be expanding on an exponential note during the forecast period.
As per the WHO, cardiovascular diseases end up consuming 17.9 million lives every single year. Cardiotoxicity is common in patients suffering from pre-existing heart conditions. It is also common in those who have undergone cardiac surgery or cancer treatment. Cardiotoxicity raises the risk to cardiomyopathy, which, in turn, decreases the capacity of heart to pump blood.
Need to combat cardiotoxicity is thus expanding the hERG screening market size.
The hERG screening market is witnessing a sizable number of innovation-based medical approvals.
For instance, in August 2023, Metrion Biosciences Limited announced that it had obtained notification from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), according to which the company is one of the members of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme, and is able to provide GLP compliant hERG ion channel screening services to life sciences community at the global level.
In October 2022, the ICH S7B Guideline and Q&A on Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential stated that it had granted permission to promote human in silico drug trials as a new tool regarding proarrhythmia risk assessment.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest hERG screening market insights, North America dominated the hERG screening industry in 2023 and the status quo is expected to remain unchanged during the forecast period. This is attributed to rise in incidence of cardiovascular disorders in the U.S. and Canada.
As per the American College of Cardiology, the U.S. witnesses an occurrence of myocardial infarction every 40 seconds. It further states that 356,460 Americans underwent out-of-hospital cardiac arrest in 2017 alone, and emergency medical services were summoned for 52% of these cases.
Besides, 18.75% of initial cardiac rhythms that were reported were ventricular tachycardia, ventricular fibrillation, or shockable by automated external defibrillator.
Europe’s significant hERG screening market share is ascribed to Germany leading from the front, followed by the U.K. Asia Pacific’s cardiac safety screening landscape is dominated by China and India and the scenario is expected to persist during the forecast period.
The key players in the hERG screening are engaging into inorganic modes of expansion including mergers, acquisitions, partnerships, and joint ventures to strengthen their position.
Abcam Limited, ABR-Affinity BioReagents, Inc., AstraZeneca plc, Aureus Sciences, AVIVA Biosciences, Cambridge Biosciences, ChanTest Corporation, Charles River Laboratories, and Chemaxon are some of the key players covered in the hERG screening market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 2.2 Bn |
| Market Forecast (Value) in 2034 | US$ 8.2 Bn |
| Growth Rate (CAGR) | 12.6% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 2.2 Bn in 2023
It is projected to grow at a CAGR of 12.6% from 2024 to 2034
Growing prevalence of heart ailments and increase in the number of innovation-based medical approvals
Gene KCNH2 type accounted for the largest share in 2023
North America was the dominant region in 2023
Abcam Limited, ABR-Affinity BioReagents, Inc., AstraZeneca plc, Aureus Sciences, AVIVA Biosciences, Cambridge Biosciences, ChanTest Corporation, Charles River Laboratories, and Chemaxon
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: hERG Screening Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. HERG Screening Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global hERG Screening Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2020-2034
6.3.1. Gene KCNH2
6.3.2. Mutant KCNH2
6.4. Market Attractiveness Analysis, by Type
7. Global hERG Screening Market Analysis and Forecast, by Ion Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Ion Channel, 2020-2034
7.3.1. Voltage-Gated
7.3.2. Ligand-Gated
7.4. Market Attractiveness Analysis, by Ion Channel
8. Global hERG Screening Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2020-2034
8.3.1. Antiarrhythmic
8.3.2. Antipsychotic
8.3.3. Antibiotics
8.3.4. Others
8.4. Market Attractiveness Analysis, by Application
9. Global hERG Screening Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America hERG Screening Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2020-2034
10.3.1. Gene KCNH2
10.3.2. Mutant KCNH2
10.4. Market Value Forecast, by Ion Channel, 2020-2034
10.4.1. Voltage-Gated
10.4.2. Ligand-Gated
10.5. Market Value Forecast, by Application, 2020-2034
10.5.1. Antiarrhythmic
10.5.2. Antipsychotic
10.5.3. Antibiotics
10.5.4. Others
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Ion Channel
10.7.3. By Application
10.7.4. By Country
11. Europe hERG Screening Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2020-2034
11.3.1. Gene KCNH2
11.3.2. Mutant KCNH2
11.4. Market Value Forecast, by Ion Channel, 2020-2034
11.4.1. Voltage-Gated
11.4.2. Ligand-Gated
11.5. Market Value Forecast, by Application, 2020-2034
11.5.1. Antiarrhythmic
11.5.2. Antipsychotic
11.5.3. Antibiotics
11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Ion Channel
11.7.3. By Application
11.7.4. By Country/Sub-region
12. Asia Pacific hERG Screening Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2020-2034
12.3.1. Gene KCNH2
12.3.2. Mutant KCNH2
12.4. Market Value Forecast, by Ion Channel, 2020-2034
12.4.1. Voltage-Gated
12.4.2. Ligand-Gated
12.5. Market Value Forecast, by Application, 2020-2034
12.5.1. Antiarrhythmic
12.5.2. Antipsychotic
12.5.3. Antibiotics
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Ion Channel
12.7.3. By Application
12.7.4. By Country/Sub-region
13. Latin America hERG Screening Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2020-2034
13.3.1. Gene KCNH2
13.3.2. Mutant KCNH2
13.4. Market Value Forecast, by Ion Channel, 2020-2034
13.4.1. Voltage-Gated
13.4.2. Ligand-Gated
13.5. Market Value Forecast, by Application, 2020-2034
13.5.1. Antiarrhythmic
13.5.2. Antipsychotic
13.5.3. Antibiotics
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Ion Channel
13.7.3. By Application
13.7.4. By Country/Sub-region
14. Middle East & Africa hERG Screening Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2020-2034
14.3.1. Gene KCNH2
14.3.2. Mutant KCNH2
14.4. Market Value Forecast, by Ion Channel, 2020-2034
14.4.1. Voltage-Gated
14.4.2. Ligand-Gated
14.5. Market Value Forecast, by Application, 2020-2034
14.5.1. Antiarrhythmic
14.5.2. Antipsychotic
14.5.3. Antibiotics
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Ion Channel
14.7.3. By Application
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Abcam Limited
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. ABR-Affinity BioReagents, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. AstraZeneca plc
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Aureus Sciences
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AVIVA Biosciences
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Cambridge Biosciences
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. ChanTest Corporation
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Charles River Laboratories
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Chemaxon
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global hERG Screening Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 02: Global hERG Screening Market Size (US$ Bn) Forecast, by Ion Channel, 2020-2034
Table 03: Global hERG Screening Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 04: Global hERG Screening Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America hERG Screening Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America hERG Screening Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 07: North America hERG Screening Market Size (US$ Bn) Forecast, by Ion Channel, 2020-2034
Table 08: North America hERG Screening Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 09: Europe hERG Screening Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe hERG Screening Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 11: Europe hERG Screening Market Size (US$ Bn) Forecast, by Ion Channel, 2020-2034
Table 12: Europe hERG Screening Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 13: Asia Pacific hERG Screening Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific hERG Screening Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 15: Asia Pacific hERG Screening Market Size (US$ Bn) Forecast, by Ion Channel, 2020-2034
Table 16: Asia Pacific hERG Screening Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 17: Latin America hERG Screening Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America hERG Screening Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 19: Latin America hERG Screening Market Size (US$ Bn) Forecast, by Ion Channel, 2020-2034
Table 20: Latin America hERG Screening Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 21: Middle East & Africa hERG Screening Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa hERG Screening Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 23: Middle East & Africa hERG Screening Market Size (US$ Bn) Forecast, by Ion Channel, 2020-2034
Table 24: Middle East & Africa hERG Screening Market Size (US$ Bn) Forecast, by Application, 2020-2034
List of Figures
Figure 01: Global hERG Screening Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global hERG Screening Market Revenue (US$ Bn), by Type, 2023
Figure 03: Global hERG Screening Market Value Share, by Type, 2023
Figure 04: Global hERG Screening Market Revenue (US$ Bn), by Ion Channel, 2023
Figure 05: Global hERG Screening Market Value Share, by Ion Channel, 2023
Figure 06: Global hERG Screening Market Revenue (US$ Bn), by Application, 2023
Figure 07: Global hERG Screening Market Value Share, by Application, 2023
Figure 08: Global hERG Screening Market Value Share, by Region, 2023
Figure 09: Global hERG Screening Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global hERG Screening Market Value Share Analysis, by Type, 2023 and 2034
Figure 11: Global hERG Screening Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global hERG Screening Market Value Share Analysis, by Ion Channel, 2023 and 2034
Figure 13: Global hERG Screening Market Attractiveness Analysis, by Ion Channel, 2024-2034
Figure 14: Global hERG Screening Market Value Share Analysis, by Application, 2023 and 2034
Figure 15: Global hERG Screening Market Attractiveness Analysis, by Application, 2024-2034
Figure 16: Global hERG Screening Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global hERG Screening Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America hERG Screening Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America hERG Screening Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America hERG Screening Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America hERG Screening Market Value Share Analysis, by Type, 2023 and 2034
Figure 22: North America hERG Screening Market Value Share Analysis, by Ion Channel, 2023 and 2034
Figure 23: North America hERG Screening Market Value Share Analysis, by Application, 2023 and 2034
Figure 24: North America hERG Screening Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America hERG Screening Market Attractiveness Analysis, by Ion Channel, 2024-2034
Figure 26: North America hERG Screening Market Attractiveness Analysis, by Application, 2024-2034
Figure 27: Europe hERG Screening Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe hERG Screening Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe hERG Screening Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe hERG Screening Market Value Share Analysis, by Type, 2023 and 2034
Figure 31: Europe hERG Screening Market Value Share Analysis, by Ion Channel, 2023 and 2034
Figure 32: Europe hERG Screening Market Value Share Analysis, by Application, 2023 and 2034
Figure 33: Europe hERG Screening Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe hERG Screening Market Attractiveness Analysis, by Ion Channel, 2024-2034
Figure 35: Europe hERG Screening Market Attractiveness Analysis, by Application, 2024-2034
Figure 36: Asia Pacific hERG Screening Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific hERG Screening Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific hERG Screening Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific hERG Screening Market Value Share Analysis, by Type, 2023 and 2034
Figure 40: Asia Pacific hERG Screening Market Value Share Analysis, by Ion Channel, 2023 and 2034
Figure 41: Asia Pacific hERG Screening Market Value Share Analysis, by Application, 2023 and 2034
Figure 42: Asia Pacific hERG Screening Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific hERG Screening Market Attractiveness Analysis, by Ion Channel, 2024-2034
Figure 44: Asia Pacific hERG Screening Market Attractiveness Analysis, by Application, 2024-2034
Figure 45: Latin America hERG Screening Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America hERG Screening Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America hERG Screening Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America hERG Screening Market Value Share Analysis, by Type, 2023 and 2034
Figure 49: Latin America hERG Screening Market Value Share Analysis, by Ion Channel, 2023 and 2034
Figure 50: Latin America hERG Screening Market Value Share Analysis, by Application, 2023 and 2034
Figure 51: Latin America hERG Screening Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America hERG Screening Market Attractiveness Analysis, by Ion Channel, 2024-2034
Figure 53: Latin America hERG Screening Market Attractiveness Analysis, by Application, 2024-2034
Figure 54: Middle East & Africa hERG Screening Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa hERG Screening Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa hERG Screening Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa hERG Screening Market Value Share Analysis, by Type, 2023 and 2034
Figure 58: Middle East & Africa hERG Screening Market Value Share Analysis, by Ion Channel, 2023 and 2034
Figure 59: Middle East & Africa hERG Screening Market Value Share Analysis, by Application, 2023 and 2034
Figure 60: Middle East & Africa hERG Screening Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa hERG Screening Market Attractiveness Analysis, by Ion Channel, 2024-2034
Figure 62: Middle East & Africa hERG Screening Market Attractiveness Analysis, by Application, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
hERG Screening Market
